Therapeutic and Safety Evaluation of the CoMiX immunoconjugates as a novel complement activation-based immunotherapy strategy

Medicine & Life Sciences

1. Immunoconjugates 100%
2. Complement Activation 99%
3. Immunotherapy 65%
4. Safety 40%
5. Neoplasms 36%
6. Lymphoma 20%
7. Complement Factor H 16%
8. Therapeutics 16%
9. Cytophagocytosis 16%
10. Drug Therapy 14%
11. Antibodies 13%
12. Biological Products 12%
13. Standard of Care 12%
14. Natural Killer Cells 11%
15. Lead 11%
16. Heterografts 11%
17. Monoclonal Antibodies 9%
18. Technology 8%
19. In Vitro Techniques 5%